OncoMatch/Clinical Trials/NCT05055908
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Is NCT05055908 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Pemetrexed plus Pembrolizumab and Pembrolizumab for lung cancer.
Treatment: Pemetrexed plus Pembrolizumab · Pembrolizumab · Pemetrexed — The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Prior therapy
Must have received: checkpoint inhibitor
Lab requirements
Blood counts
adequate bone marrow hematopoiesis
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate bone marrow hematopoiesis and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05055908 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received checkpoint inhibitor.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify